Mycamine is indicated in adult and pediatric patients 4 months and older for: Treatment of Patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses [see Pharmacology: Clinical Studies under Actions]. Mycamine has not been adequately studied in patients with endocarditis, osteomyelitis and meningitis due to Candida infections.
Treatment of Patients with Esophageal Candidiasis [see Pharmacology: Clinical Studies under Actions].
Prophylaxis of Candida Infections in Patients Undergoing Hematopoietic Stem Cell Transplantation [see Pharmacology: Clinical Studies under Actions].
NOTE: The efficacy of Mycamine against infections caused by fungi other than Candida has not been established.